Funded by the National Science Foundation and the National Institutes of Health, Kao's research uses a reverse engineering strategy to learn from and exploit drug-company mutants--in this case the bacterial species that produces erythromycin, an antibiotic given to treat bronchitis, diphtheria, whooping cough, pneumonia and other conditions.